Letter by Xu Regarding Article, “Shear-Induced CCN1 Promotes Atheroprone Endothelial Phenotypes and Atherosclerosis”
Pei-Ling Hsu,Jheng-Sin Chen,Chin-Yung Wang,Hua-Lin Wu,Fan-E Mo
DOI: https://doi.org/10.1161/circulationaha.119.041169
IF: 37.8
2019-01-01
Circulation
Abstract:HomeCirculationVol. 140, No. 20Letter by Xu Regarding Article, “Shear-Induced CCN1 Promotes Atheroprone Endothelial Phenotypes and Atherosclerosis” Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBLetter by Xu Regarding Article, “Shear-Induced CCN1 Promotes Atheroprone Endothelial Phenotypes and Atherosclerosis” Suowen Xu, PhD Suowen XuSuowen Xu Aab Cardiovascular Research Institute (CVRI), Department of Medicine, University of Rochester School of Medicine and Dentistry, NY. Search for more papers by this author Originally published11 Nov 2019https://doi.org/10.1161/CIRCULATIONAHA.119.041169Circulation. 2019;140:e766–e767To the Editor:The CCN family of matricellular proteins (CCN1, CCN2, and CCN3) comprises mechanosensitive proteins that are differentially regulated by shear stress, the frictional force exerted by the blood flow. Previous studies have shown that disturbed blood flow upregulates CCN1 (also known as CYR61) and CCN2 (also known as CTGF) expression1; however, unidirectional laminar blood flow decreases CCN1 and CCN2 expression,1 while increasing CCN3 (also known as NOV expression).2 The direct role of CCN3 (prevents atherosclerosis) in atherosclerosis has been recently demonstrated in an atherosusceptible mouse strain.3 However, it remains elusive whether CCN1 also plays a decisive role in atherosclerosis in vivo.A recent study by Hsu et al4 has elegantly shown that CCN1 directly promotes atherosclerosis in mice by creating a knock-in mouse strain carrying the integrin α6β1-binding–defective mutant allele Ccn1dm/dm on the atheroprone Apoe–/– mouse background. The authors observed the upregulation of endothelial CCN1 in response to ligation surgery. Ccn1dm/dm/Apoe–/– mice also protects against ligation and diet-induced atherosclerotic plaque formation, concurrent with reduced oxidative stress, decreased expression of endothelin-1 and monocyte chemoattractant protein-1, and reduced monocyte homing.4 Mechanistically, CCN1/α6β1 is involved in transcription factor nuclear factor-κB (NF-κB) and downstream atheroprone gene expression in vitro and in vivo. Another interesting observation is that NF-κB activation induced by activated CCN1/α6β1 signaling further amplifies the production of CCN1 and α6β1, constituting a positive feedback loop, which was disrupted by blocking CCN1-α6β1 binding.4 By disrupting the feedback loop pf CCN1/α6β1–NF-κB–CCN1/α6β1, disturbed flow-induced atheroprone phenotype and lesion formation was ameliorated in mice. This study highlights the therapeutic potential to treat atherosclerosis by pharmacologically inhibiting CCN1-α6β1, such as the use of the T1 peptide (which was derived from the α6β1-binding sequence of CCN1).4Because no tissue (endothelial cell)-specific mice were used, the precise role of endothelial cell–derived CCN1 in atheroprogression remains to be established. In addition to NF-kB activation by activated CCN1-α6β1 signaling, another intriguing possibility would be that the Hippo pathway effector YAP/TAZ pathway may also play an important role in the transcription of CCN1 (and CCN2, as well).1 Because CCN1 is a well-established downstream target of YAP/TAZ in endothelial cells, further experiments elucidating the involvement of YAP/TAZ in the vicious cycle of CCN1/α6β1–NF-κB are necessary to address this question. Simultaneously with the publication of this article, another recent article by Zhao et al5 also shows a similar phenotype by treating Apoe–/– mice with CCN1. Specifically, CCN1 (10 µg·kg–1·d–1, intraperitoneally, 4 weeks) promotes systemic inflammation and atherosclerosis development in ApoE–/– mice by impairing reverse cholesterol transport (cholesterol efflux) without affecting lipid uptake. Gain- and loss-of-function assays in cultured macrophages indicated that CCN1 drives lipid accumulation and foam cell formation by impairing ABCA1 (G1)-mediated cholesterol efflux, suggesting that macrophage CCN1 also plays a proatherogenic role.5 Both studies suggest that targeting CCN1 expression/secretion may hold promise to treat atherosclerosis. It remains to be evaluated whether CCN1 represents a useful diagnostic biomarker for atherosclerosis and plaque vulnerability in human patients.DisclosuresNone.Footnoteshttps://www.ahajournals.org/journal/circReferences1. Wang KC, Yeh YT, Nguyen P, Limqueco E, Lopez J, Thorossian S, Guan KL, Li YJ, Chien S. Flow-dependent YAP/TAZ activities regulate endothelial phenotypes and atherosclerosis.Proc Natl Acad Sci U S A. 2016; 113:11525–11530. doi: 10.1073/pnas.1613121113CrossrefMedlineGoogle Scholar2. Lin Z, Natesan V, Shi H, Hamik A, Kawanami D, Hao C, Mahabaleshwar GH, Wang W, Jin ZG, Atkins GB, et al. A novel role of CCN3 in regulating endothelial inflammation.J Cell Commun Signal. 2010; 4:141–153. doi: 10.1007/s12079-010-0095-xCrossrefMedlineGoogle Scholar3. Shi H, Zhang C, Pasupuleti V, Hu X, Prosdocimo DA, Wu W, Qing Y, Wu S, Mohammad H, Gerson SL, et al. CCN3 regulates macrophage foam cell formation and atherosclerosis.Am J Pathol. 2017; 187:1230–1237. doi: 10.1016/j.ajpath.2017.01.020CrossrefMedlineGoogle Scholar4. Hsu PL, Chen JS, Wang CY, Wu HL, Mo FE. Shear-induced CCN1 promotes atheroprone endothelial phenotypes and atherosclerosis.Circulation. 2019; 139:2877–2891. doi: 10.1161/CIRCULATIONAHA.118.033895LinkGoogle Scholar5. Zhao JF, Chen HY, Wei J, Jim Leu SJ, Lee TS. CCN family member 1 deregulates cholesterol metabolism and aggravates atherosclerosis.Acta Physiol (Oxf). 2019; 225:e13209. doi: 10.1111/apha.13209CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetails November 12, 2019Vol 140, Issue 20 Advertisement Article InformationMetrics © 2019 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.119.041169PMID: 31710525 Originally publishedNovember 11, 2019 PDF download Advertisement